Drug intelligence / Profile preview

PCV20 + LVA

Development stage
Unknown
Lead developer
Pfizer
Modality
Vaccines & Immunotherapeutics
Administration
Intramuscular
01

Overview

PCV20 + LVA is a combination vaccine composed of the 20-valent pneumococcal conjugate vaccine (PCV20) and 1 mg of LVA immunoadjuvant. PCV20 is designed to protect against invasive disease and pneumonia caused by 20 different serotypes of Streptococcus pneumoniae. The vaccine is made of purified capsular polysaccharides from these serotypes, each conjugated to the CRM197 carrier protein, which enhances immune response. The LVA component is an immunoadjuvant intended to further boost the immunogenicity of the vaccine. This combination is under investigation, with one formulation (PCV-LITE) consisting of a 1/5th dose of PCV20 plus 1 mg LVA, and another with a full dose of PCV20 plus 1 mg LVA. PCV20 is manufactured by Wyeth Pharmaceuticals (Pfizer). The principal indication is the prevention of invasive disease and pneumonia caused by S. pneumoniae. The LVA adjuvant enhances the immune response to the vaccine antigens[1][2][7].

Other names
PCV-LITE
02

Targets

CPS (Streptococcus pneumoniae capsular polysaccharide)

Beyond the preview

Go deeper on PCV20 + LVA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on PCV20 + LVA.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call